Gut bacteria may help bladder cancer patients avoid surgery
NCT ID NCT07474064
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding a probiotic (Clostridium butyricum) to a combination of targeted therapy (Disitamab Vedotin) and immunotherapy (Toripalimab) can help preserve the bladder in people with muscle-invasive bladder cancer who cannot take the chemotherapy drug cisplatin. About 146 participants will receive either the probiotic plus the drug combo or the drug combo alone for one year. The main goal is to see if the probiotic extends the time the bladder remains cancer-free without needing removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Probiotic (Clostridium butyricum), Disitamab Vedotin, Toripalimab
What this could lead to
If it works, this could offer a way to treat muscle-invasive bladder cancer without removing the bladder, potentially improving quality of life for patients who cannot take standard chemotherapy.
What could go wrong
This is a phase 2 trial with only 146 participants, so results are preliminary. The combination therapy may cause side effects, and the benefit of probiotics is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MUSCLE-INVASIVE BLADDER CANCER (MIBC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, 510120, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact